# Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

> **NCT03463187** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 211 (actual)

## Conditions studied

- Moderate-to-severe Chronic Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** SHR-1314
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03463187
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-15
- **Primary completion:** 2020-08-31
- **Final completion:** 2020-08-31
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03463187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03463187, "Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03463187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*